Should I buy or sell Cognition Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGTX shares. View CGTX analyst ratings or view top-rated stocks .

What is Cognition Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 1-year price targets for Cognition Therapeutics' shares. Their CGTX share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 358.0% from the stock's current price. View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts .

How have CGTX shares performed in 2023?

Cognition Therapeutics' stock was trading at $2.10 at the beginning of 2023. Since then, CGTX stock has decreased by 37.6% and is now trading at $1.31. View the best growth stocks for 2023 here .

Are investors shorting Cognition Therapeutics?

Cognition Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 240,200 shares, a drop of 19.1% from the October 31st total of 296,800 shares. Based on an average trading volume of 98,900 shares, the short-interest ratio is currently 2.4 days. Currently, 1.1% of the shares of the company are sold short. View Cognition Therapeutics' Short Interest .

When is Cognition Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our CGTX earnings forecast .

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.09.

When did Cognition Therapeutics IPO?

(CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

Who are Cognition Therapeutics' major shareholders?

Cognition Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Steward Financial Group LLC (0.13%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace . View institutional ownership trends .

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cognition Therapeutics Stock Price, News & Analysis (NASDAQ:CGTX)

$1.31

-0.06 (-4.38%)

(As of 12/5/2023 ET)

Compare

Today's Range: $1.26
▼
$1.41
50-Day Range: $0.96
▼
$1.44
52-Week Range: $0.90
▼
$3.49

Volume: 40,250 shs
Average Volume: 100,464 shs
Market Capitalization: $39.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Cognition Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 358.0% Upside
$6.00 Price Target
Short Interest: Healthy
1.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.93) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

257th out of 948 stocks

Biological Products, Except Diagnostic Industry

33rd out of 148 stocks

3.5

Analyst's Opinion

Consensus Rating
Cognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Cognition Therapeutics has a forecasted upside of 358.0% from its current price of $1.31.
Amount of Analyst Coverage
Cognition Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.10% of the float of Cognition Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cognition Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cognition Therapeutics has recently decreased by 19.07%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cognition Therapeutics does not currently pay a dividend.
Dividend Growth
Cognition Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CGTX.

2.2

News and Social Media Coverage

News Sentiment
Cognition Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cognition Therapeutics this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.80% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.43% of the stock of Cognition Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cognition Therapeutics are expected to decrease in the coming year, from ($0.93) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cognition Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cognition Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cognition Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CGTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGTX Stock News Headlines

December 4, 2023 | americanbankingnews.com

Critical Review: Cognition Therapeutics (NASDAQ:CGTX) vs. Invivyd (NASDAQ:IVVD)

November 22, 2023 | morningstar.com

Cognition Therapeutics Inc CGTX

December 5, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

November 16, 2023 | finance.yahoo.com

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

November 15, 2023 | stockhouse.com

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases

November 15, 2023 | finance.yahoo.com

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

November 7, 2023 | benzinga.com

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

November 7, 2023 | finance.yahoo.com

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

December 5, 2023 | Edge On The Street (Ad)

U.S. Military Defense Fails Without Vanadium?

The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.

November 3, 2023 | finance.yahoo.com

Cognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial Results

November 2, 2023 | msn.com

Cognition Therapeutics GAAP EPS of $0.22 beats by $0.46

November 2, 2023 | finance.yahoo.com

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

October 27, 2023 | finance.yahoo.com

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

October 24, 2023 | stockhouse.com

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD

October 24, 2023 | finance.yahoo.com

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

October 16, 2023 | finance.yahoo.com

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

September 27, 2023 | thestreet.com

Cognition Therapeutics Inc.

September 7, 2023 | finance.yahoo.com

Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD

August 30, 2023 | finance.yahoo.com

Cognition Therapeutics Announces Participation in Upcoming September Conferences

August 14, 2023 | msn.com

Ladenburg Thalmann Maintains Cognition Therapeutics (CGTX) Buy Recommendation

August 9, 2023 | finance.yahoo.com

Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely?

August 9, 2023 | finance.yahoo.com

Q2 2023 Cognition Therapeutics Inc Earnings Call

August 8, 2023 | finanznachrichten.de

Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 8, 2023 | finance.yahoo.com

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 8, 2023 | benzinga.com

Cognition Therapeutics's Earnings Outlook

August 8, 2023 | finance.yahoo.com

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 2, 2023 | finance.yahoo.com

Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023

See More Headlines

Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CGTX
CUSIP: N/A
CIK: 1455365
Web: www.cogrx.com
Phone: 412-481-2210
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +358.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,400,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -65.53%
Return on Assets: -51.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.38
Quick Ratio: 4.38

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.39 per share
Price / Book: 0.94

Miscellaneous

Outstanding Shares: 30,420,000
Free Float: 23,178,000
Market Cap: $39.85 million
Optionable: Not Optionable
Beta: 1.36

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Lisa Ricciardi (Age 63)
CEO, President & Director
Comp: $794.04k
Dr. Anthony O. Caggiano M.D.
Ph.D., Chief Medical Officer and Head of R&D
Mr. John Brendan Doyle (Age 46)
Chief Financial Officer
Dr. Steven A. Weissman Ph.D.
VP & Head of CMC

Key Competitors

View All Competitors

Institutional Ownership

Steward Financial Group LLC
Bought 40,874 shares on 10/23/2023
Ownership: 0.135%

View All Institutional Transactions

CGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cognition Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGTX shares.
View CGTX analyst ratings or view top-rated stocks.
What is Cognition Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 1-year price targets for Cognition Therapeutics' shares. Their CGTX share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 358.0% from the stock's current price.
View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts.
How have CGTX shares performed in 2023?: Cognition Therapeutics' stock was trading at $2.10 at the beginning of 2023. Since then, CGTX stock has decreased by 37.6% and is now trading at $1.31.
View the best growth stocks for 2023 here.
Are investors shorting Cognition Therapeutics?: Cognition Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 240,200 shares, a drop of 19.1% from the October 31st total of 296,800 shares. Based on an average trading volume of 98,900 shares, the short-interest ratio is currently 2.4 days. Currently, 1.1% of the shares of the company are sold short.
View Cognition Therapeutics' Short Interest.
When is Cognition Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our CGTX earnings forecast.

How were Cognition Therapeutics' earnings last quarter?: Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.09.
When did Cognition Therapeutics IPO?: (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.
Who are Cognition Therapeutics' major shareholders?: Cognition Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Steward Financial Group LLC (0.13%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace.
View institutional ownership trends.
How do I buy shares of Cognition Therapeutics?: Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CGTX) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial